Epstein Secrets

From: Lesley Groff <1 To: David Carter c4 Subject: Re: Investment Opportunities Date: Fri, 06 Mar 2015 15:42:18 +0000 terrific. I will forward on...thanks On Mar 6, 2015, at 10:28 AM,

civic minded interest". (The Russians Love OvationBio, but we need to show them "proof of concept", before they can/will invest.) ConcentRx: I like ConcentRx. It is personalized cancer therapy. We will only beat cancer when we learn to treat it individually, and one patient at a time. I am pretty sue I h

Opportunities-David Carter Date: Fri, 06 Mar 2015 15:42:07 +0000 Attachments: DaCart_Presentation Mar 2 2015.pptx Begin forwarded message: From: "David Carter" < Subject: FW: Investment Opportunities Date: March 6, 2015 at 10:28:30 AM EST To: From: David Carter [madto: Sent: Thursday, March 05, 2015 11

civic minded interest". (The Russians Love OvationBio, but we need to show them "proof of concept", before they can/will invest.) ConcentRx: I like ConcentRx. It is personalized cancer therapy. We will only beat cancer when we learn to treat it individually, and one patient at a time. I am pretty sue I h

From: "David Carter" To:' <Ma> Subject: FW: Investment Opportunities Date: Fri, 06 Mar 2015 15:28:30 +0000 Attachments: DaCart_Presentation_Mar_2_2015.pptx From: D

civic minded interest". (The Russians Love OvationBio, but we need to show them "proof of concept", before they can/will invest.) ConcentRx: I like ConcentRx. It is personalized cancer therapy. We will only beat cancer when we learn to treat it individually, and one patient at a time. I am pretty sue I h

lable USA Cleantech Fund #1 $35M ■ $25M Institutional ■ 16 Units @ $625K/Unit ■ Available DACART CAPITAL LLC EFTA_R1_01138806 EFTA02295532 David Carter, Managing Director • 25+ years executive-level experience • Chairman, CEO/President - 7 companies • Co-founder - 3 companies • 3 M&A's, 1 IPO •

combining an appropriate autologous immune cell with an appropriate tumor cell antigen can achieve a demonstrable oncolytic effect in humans. The ConcentRx technology platform further advances the state of the art in autologous immune cell cancer therapies by: • Employing the patient's own enriched, ac

5M/Unit ■ Available USA Cleantech Fund #1 (USivt ■ $25M Institutional ■ 16 Units @ $625K/Unit ■ Available DAGAR C_APII AL LL, EFTA00506111 David Carter, Managing Director • 25+ years executive-level experience • Chairman, CEO/President - 7 companies • Co-founder - 3 companies • 3 , 1 IPO • >$50

combining an appropriate autologous immune cell with an appropriate tumor cell antigen can achieve a demonstrable oncolytic effect in humans. The ConcentRx technology platform further advances the state of the art in autologous immune cell cancer therapies by: • Employing the patient's own enriched, ac